AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32392558 — intervention group
Group type: EXPERIMENTAL
Intervention: High NETest (>40) including fibrosome/NEDome
Number of subjects: 222
Study 32392558 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of four omes (epigenome, metastasome, fibrosome, NEDome) with NETest score
Number of subjects: 222
Study 32392558 — intervention group
Group type: COMPARATOR
Intervention: Twelve omes excluding inflammasome and apoptome
Number of subjects: 222
Study 32392558 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven omes (proliferome, NEDome, epigenome, SSTRome, neurome, metastasome, fibrosome)
Number of subjects: 222
Study 32392558 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven omes
Number of subjects: 222
Study 32392558 — intervention group
Group type: EXPERIMENTAL
Intervention: Septet omic expression
Number of subjects: 222
Study 32392558 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of quartet (epigenome, fibrosome, metastasome, NEDome) and NETest score
Number of subjects: 222
Study 32393184 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: PCP counseling/encouragement, in-office tele-HS, and educational materials
Number of subjects: 660
Study 32393184 — intervention group
Group type: COMPARATOR
Intervention: Group 2: PCP counseling/encouragement on importance of hearing screening, instructions to take the tele-HS from home, educational materials
Number of subjects: 660
Study 32393184 — intervention group
Group type: COMPARATOR
Intervention: Group 1: Instructions for tele-HS to complete at home and educational materials on warning signs and consequences of hearing loss
Number of subjects: 660
Study 32393184 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (fail tele-HS)
Number of subjects: 660
Study 32393184 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 660
Study 32393207 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vitamin D levels
Number of subjects: 67
Study 32393207 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alkaline phosphatase levels
Number of subjects: 67
Study 32393207 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobb angles, spinal bone mass densities
Number of subjects: 67
Study 32393288 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive mapping that was iteratively updated by recalculating the principal components based on ongoing movements.
Number of subjects: 20
Study 32393288 — intervention group
Group type: COMPARATOR
Intervention: Fixed mapping throughout the experiment.
Number of subjects: 20
Study 32393328 — intervention group
Group type: EXPERIMENTAL
Intervention: zanubrutinib
Number of subjects: 91
Study 32393334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home-visiting program
Number of subjects: 739
Study 32393350 — intervention group
Group type: COMPARATOR
Intervention: ASD group
Number of subjects: 165
Study 32393350 — intervention group
Group type: COMPARATOR
Intervention: Over-responsive subgroup (n = 35)
Number of subjects: 165
Study 32393350 — intervention group
Group type: COMPARATOR
Intervention: Under-responsive subgroup (n = 89)
Number of subjects: 165
Study 32393350 — intervention group
Group type: COMPARATOR
Intervention: Under-responsive group
Number of subjects: 165
Study 32393350 — intervention group
Group type: COMPARATOR
Intervention: Over-responsive subgroup
Number of subjects: 165
Study 32393358 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth phenotyping and omics assessments
Number of subjects: 1500
Study 32393358 — intervention group
Group type: EXPERIMENTAL
Intervention: Validated paradigms (e.g., fear conditioning, reward anticipation, imaging stress test, social reward learning task)
Number of subjects: 1500
Study 32393358 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel assessments (genetic, molecular, cellular, physiological, neuroimaging, neurocognitive, psychophysiological, psychometric)
Number of subjects: 1500
Study 32394292 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OACs) including dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban
Number of subjects: 62888
Study 32394403 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal perfusion (defined as a summed stress score (SSS) ≥ 4)
Number of subjects: 404
Study 32394403 — intervention group
Group type: EXPERIMENTAL
Intervention: Inability to exercise > 4 METs
Number of subjects: 404
Study 32394403 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined assessment of functional status and myocardial perfusion
Number of subjects: 404
Study 32394403 — intervention group
Group type: COMPARATOR
Intervention: Normal perfusion
Number of subjects: 404
Study 32394598 — intervention group
Group type: EXPERIMENTAL
Intervention: CAA-related ICH patients
Number of subjects: 36
Study 32394598 — intervention group
Group type: COMPARATOR
Intervention: Controls with deep ICH
Number of subjects: 36
Study 32395294 — intervention group
Group type: EXPERIMENTAL
Intervention: SV-VATS (non-intubated spontaneous ventilation)
Number of subjects: 316
Study 32395294 — intervention group
Group type: COMPARATOR
Intervention: MV-VATS (intubated mechanical ventilation)
Number of subjects: 316
Study 32395337 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 or 100 mg
Number of subjects: 25
Study 32395501 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprocedural aggressive hydration
Number of subjects: 560
Study 32395501 — intervention group
Group type: COMPARATOR
Intervention: General hydration
Number of subjects: 560
Study 32395547 — intervention group
Group type: EXPERIMENTAL
Intervention: Extubation success within 48 hours following endotracheal tube removal
Number of subjects: 1500
Study 32395547 — intervention group
Group type: EXPERIMENTAL
Intervention: Various time-frames for extubation success rate (within 96 hours, >96 hours after extubation)
Number of subjects: 1500
Study 32395547 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of existing prediction scores for successful extubation
Number of subjects: 1500
Study 32395547 — intervention group
Group type: EXPERIMENTAL
Intervention: Current practices of extubation and tracheostomy
Number of subjects: 1500
Study 32395709 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) administered via implanted intra-cerebroventricular delivery system at a maximum dose of 160 mg/day
Number of subjects: 5
Study 32395709 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) administered via implanted intra-cerebroventricular delivery system
Number of subjects: 5
Study 32396014 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus 5-FU+CDDP (cisplatin and 5-fluorouracil)
Number of subjects: 0
Study 32396014 — intervention group
Group type: EXPERIMENTAL
Intervention: One prior administration of nivolumab and the cohort A regimen (5-FU+CDDP)
Number of subjects: 0
Study 32396014 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus docetaxel+ CF (cisplatin and 5-fluorouracil)
Number of subjects: 0
Study 32396014 — intervention group
Group type: EXPERIMENTAL
Intervention: One prior administration of nivolumab and the cohort C regimen (docetaxel+ CF)
Number of subjects: 0
Study 32396475 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of protective barrier during sexual activity
Number of subjects: 141
Study 32396615 — intervention group
Group type: EXPERIMENTAL
Intervention: CWP232291 (CWP291) administered IV daily for 7 days every 21 days
Number of subjects: 69
Study 32397857 — intervention group
Group type: EXPERIMENTAL
Intervention: ABTL0812
Number of subjects: 0
Study 32397857 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological manipulation to increase cellular dihydroceramides or incubation with exogenous dihydroceramides
Number of subjects: 0
Study 32398128 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodermal activity (EDA) assessment during exposure therapy
Number of subjects: 34
Study 32398128 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective Units of Distress Scale (SUDS) during exposure therapy
Number of subjects: 34
Study 32398128 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait physiological arousal survey
Number of subjects: 34
Study 32398156 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamas participation (group-based health education and microfinance program)
Number of subjects: 326
Study 32398156 — intervention group
Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 326
Study 32398308 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 0
Study 32398308 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 0
Study 32398351 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased glucose variability (GV) measured as standard deviation (SD) and coefficient of variation (CV) during the last day of hospitalization.
Number of subjects: 1042150
Study 32398478 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg subcutaneously
Number of subjects: 5
Study 32398792 — intervention group
Group type: EXPERIMENTAL
Intervention: elotuzumab therapy
Number of subjects: 0
Study 32399045 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Marrow Concentrate (BMC) with Platelet-Rich Plasma (PRP) and Platelet Lysate (PL) injections
Number of subjects: 25
Study 32399045 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 25
Study 32399187 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32399214 — intervention group
Group type: EXPERIMENTAL
Intervention: shRNA-IL6-modified anti-CD19 CAR-T therapy (ssCAR-T-19)
Number of subjects: 1
Study 32399254 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-AFTERc intervention delivered by specialist breast cancer nurses (SBCNs) over the telephone, structured 30-min counselling intervention.
Number of subjects: 0
Study 32399254 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 32399263 — intervention group
Group type: EXPERIMENTAL
Intervention: MVT-5873 (a cytotoxic monoclonal antibody targeting CA 19-9) administered as a single dose three days before resection and four post-operative infusions.
Number of subjects: 0
Study 32399595 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra- and/or postoperative blood transfusion(s)
Number of subjects: 1546
Study 32399595 — intervention group
Group type: EXPERIMENTAL
Intervention: American Society of Anesthesiologists class III vs I-II
Number of subjects: 1546
Study 32399595 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra- vs intra-corporeal anastomosis
Number of subjects: 1546
Study 32399595 — intervention group
Group type: EXPERIMENTAL
Intervention: Female vs male gender
Number of subjects: 1546
Study 32399595 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of the procedure
Number of subjects: 1546
Study 32399595 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 1546
Study 32399622 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed PET radioligand
Number of subjects: 10
Study 32399622 — intervention group
Group type: COMPARATOR
Intervention: One- and unconstrained two-tissue compartment models, Logan graphical analysis
Number of subjects: 10
Study 32399752 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian penalized likelihood (BPL) reconstruction algorithm
Number of subjects: 20
Study 32399752 — intervention group
Group type: COMPARATOR
Intervention: OSEM reconstruction
Number of subjects: 20
Study 32399958 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks until loss of clinical benefit or unacceptable toxicity
Number of subjects: 25
Study 32401215 — intervention group
Group type: EXPERIMENTAL
Intervention: TV-AssistDem (TeleVision-based ASSistive Integrated Service)
Number of subjects: 93
Study 32401215 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 93
Study 32401225 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media intervention with financial incentives
Number of subjects: 955
Study 32401225 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media intervention without financial incentives (SMI)
Number of subjects: 955
Study 32401225 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo control (entertaining social media content)
Number of subjects: 955
Study 32401293 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative SURPASS checklist
Number of subjects: 9009
Study 32401293 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative SURPASS checklist
Number of subjects: 9009
Study 32401293 — intervention group
Group type: COMPARATOR
Intervention: Parallel control units
Number of subjects: 9009
Study 32401293 — intervention group
Group type: COMPARATOR
Intervention: Control group (WHO SSC only)
Number of subjects: 9009
Study 32401302 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/Obese (OW) mothers' human milk
Number of subjects: 174
Study 32401302 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of OW mothers
Number of subjects: 174
Study 32401302 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk insulin and leptin
Number of subjects: 174
Study 32401302 — intervention group
Group type: EXPERIMENTAL
Intervention: Macronutrients in human milk
Number of subjects: 174
Study 32401592 — intervention group
Group type: EXPERIMENTAL
Intervention: multi-component intervention
Number of subjects: 0
Study 32401707 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL/kg 0.25% bupivacaine (Group B)
Number of subjects: 86
Study 32401707 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL/kg 0.25% bupivacaine + 3 mg/kg 1% lidocaine (Group BL)
Number of subjects: 86
Study 32401707 — intervention group
Group type: COMPARATOR
Intervention: Intra-operative intravenous fentanyl use
Number of subjects: 86
Study 32401731 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of resident movements using a wearable sensor and observation of repositioning events.
Number of subjects: 2
Study 32401731 — intervention group
Group type: EXPERIMENTAL
Intervention: Braden Pressure Ulcer Risk Assessment conducted weekly.
Number of subjects: 2
Study 32401744 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin (LAMA) and Formoterol Fumarate (LABA) inhalation solution admixture
Number of subjects: 0
Study 32402161 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactin-V
Number of subjects: 228
Study 32402161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 32402922 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (surgery)
Number of subjects: 97
Study 32403243 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for six weeks
Number of subjects: 25
Study 32403243 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no aerobic exercise)
Number of subjects: 25
Study 32403379 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal anthralin gel
Number of subjects: 0
Study 32403379 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethosomal anthralin gel
Number of subjects: 0
Study 32403379 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32404003 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference work in psychodynamic therapy
Number of subjects: 0
Study 32404003 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 32404008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercaloric diet
Number of subjects: 15
Study 32404008 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=5)
Number of subjects: 15
Study 32404091 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment of pancreatic metastases
Number of subjects: 26
Study 32404437 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin at 75-100 mg/kg/day divided doses
Number of subjects: 0
Study 32404437 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular gentamicin
Number of subjects: 0
Study 32404502 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects in northern China
Number of subjects: 119
Study 32404502 — intervention group
Group type: COMPARATOR
Intervention: Subjects in southern China
Number of subjects: 119
Study 32404868 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 plus abiraterone/prednisone
Number of subjects: 625
Study 32404868 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 plus enzalutamide
Number of subjects: 625
Study 32404868 — intervention group
Group type: COMPARATOR
Intervention: Radium-223
Number of subjects: 625
Study 32404868 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 with bone health agents (BHAs)
Number of subjects: 625
Study 32405431 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus supplementation (400 mg) with glucose
Number of subjects: 12
Study 32405431 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose without phosphorus)
Number of subjects: 12
Study 32405623 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg albendazole (PSAC)
Number of subjects: 333
Study 32405623 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg albendazole (SAC)
Number of subjects: 333
Study 32405623 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg albendazole (Adults)
Number of subjects: 333
Study 32405623 — intervention group
Group type: EXPERIMENTAL
Intervention: Any adverse event
Number of subjects: 333
Study 32406487 — intervention group
Group type: EXPERIMENTAL
Intervention: PrOD (paritaprevir-ritonavir-ombitasvir plus dasabuvir) for 12 weeks
Number of subjects: 45
Study 32406487 — intervention group
Group type: EXPERIMENTAL
Intervention: PrOD (paritaprevir-ritonavir-ombitasvir plus dasabuvir) for 24 weeks
Number of subjects: 45
Study 32406487 — intervention group
Group type: EXPERIMENTAL
Intervention: PrOD (paritaprevir-ritonavir-ombitasvir plus dasabuvir)
Number of subjects: 45
Study 32406862 — intervention group
Group type: EXPERIMENTAL
Intervention: VoiceSense digital voice analysis tool analyzing 200 specific speech parameters
Number of subjects: 254
Study 32406862 — intervention group
Group type: COMPARATOR
Intervention: Psychological questionnaires (SCL-90, PHQ, Big 5 Test)
Number of subjects: 254
Study 32406919 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory dietary changes
Number of subjects: 0
Study 32406919 — intervention group
Group type: COMPARATOR
Intervention: Pro-inflammatory dietary changes
Number of subjects: 0
Study 32406978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryptogenic stroke patients
Number of subjects: 60
Study 32406978 — intervention group
Group type: COMPARATOR
Intervention: Lowest tertile of cryptogenic stroke patients
Number of subjects: 60
Study 32406978 — intervention group
Group type: COMPARATOR
Intervention: Stroke-free controls
Number of subjects: 60
Study 32407157 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive Tracheobronchial Aspergillosis treatment; specific intervention details not available
Number of subjects: 0
Study 32407157 — intervention group
Group type: COMPARATOR
Intervention: Control group; specific details not available
Number of subjects: 0
Study 32407247 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor skill training
Number of subjects: 0
Study 32407400 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal genetic locus ITPR1 (rs746039 [G])
Number of subjects: 1849
Study 32407400 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased placental expression of ITPR1
Number of subjects: 1849
Study 32407400 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score composed of known maternal SNPs
Number of subjects: 1849
Study 32407591 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 200 mg (subcutaneous)
Number of subjects: 14
Study 32407591 — intervention group
Group type: COMPARATOR
Intervention: Probe cocktail (midazolam, S-warfarin, omeprazole, dextromethorphan, caffeine)
Number of subjects: 14
Study 32407672 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32407888 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexican-born parents
Number of subjects: 165
Study 32407888 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent depression
Number of subjects: 165
Study 32407888 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental Support
Number of subjects: 165
Study 32407888 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential years in the United States
Number of subjects: 165
Study 32408111 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus lamivudine
Number of subjects: 41
Study 32408387 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone oil
Number of subjects: 601
Study 32408387 — intervention group
Group type: COMPARATOR
Intervention: Sulfur hexafluoride (SF6)
Number of subjects: 601
Study 32408397 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 38
Study 32408397 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study 32408769 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of electronic health records in the STRIDE trial
Number of subjects: 0
Study 32408828 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic parameters for assessing MR severity
Number of subjects: 159
Study 32408828 — intervention group
Group type: EXPERIMENTAL
Intervention: PISA-based regurgitant volume, PISA-based effective regurgitant orifice area, and vena contracta
Number of subjects: 159
Study 32408984 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cells (CAR-T)
Number of subjects: 0
Study 32409206 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma OPN levels at day 1
Number of subjects: 957
Study 32409206 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of OPN levels during the first 7 days
Number of subjects: 957
Study 32409206 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma OPN at day 1
Number of subjects: 957
Study 32410049 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic adherence counseling and cognitive behavioral therapy
Number of subjects: 27
Study 32410080 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg twice daily plus cetuximab (weekly intravenous at approved dose)
Number of subjects: 13
Study 32410080 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib (150, 300, and 400 mg) plus cetuximab
Number of subjects: 13
Study 32410147 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg/day on 5 consecutive days at baseline and on 3 consecutive days 12 months later
Number of subjects: 811
Study 32410305 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents with elevated depressive symptoms
Number of subjects: 128